The products and information provided on this website are intended for healthcare professionals. These products are not for sale or distribution in the United States and statements made regarding these products have not been evaluated by the U.S. Food and Drug Administration (FDA). The efficacy of these products has not been confirmed by FDA-approved research and these products are therefore not intended to diagnose, treat, cure or prevent any disease. All information presented here is for general information purposes only and not meant as a substitute for or alternative to advice from healthcare practitioners. The Federal Food, Drug and Cosmetic Act requires this notice.
Successful satellite symposium at the annual meeting of the DGTHG in Hamburg
This February it was finally time again: After a two-year break in attendance due to the Covid pandemic, the Annual Meeting of the German Society for Thoracic Cardiac and Vascular Surgery (DGTHG) and the 54th Annual Meeting of the German Society for Pediatric Cardiology and Congenital Heart Defects (DGPK) could take place live again. This year’s motto was: “Special forces as a team”. Resuscitec GmbH presented itself alongside many other exhibitors at the start of the trade fair on February 11, 2023 with its own booth in the Hamburg Congress Center. “We were able to get in direct contact with some physicians who were not yet familiar with CARL and could present the CARL Technology to them live on site,” says Patrick Rauh, Commercial Director at Resuscitec GmbH.
More than 60 participants attended the satellite symposium on “CARL. From cardiopulmonary resuscitation to controlled reperfusion of the whole body” on Sunday, February 12. Hug Aubin from the University Hospital Düsseldorf spoke about in-hospital experiences with CARL, Maik Foltan from the University Hospital Regensburg presented the results of out-of-hospital interventions. In addition, Dirk Buchwald from the University Hospital Bergmannsheil reported in his presentation on his CARL-specific experiences in everyday clinical practice. Finally, Christoph Benk from Resuscitec GmbH presented the latest multicenter clinical results on CARL.